###### Key messages

Why is the key question?
========================

-   Can a core set of outcome measures that are reliable and feasible be identified by experts for use in future clinical trials in connective tissue disease associated interstitial lung disease (CTD-ILD) and idiopathic pulmonary fibrosis (IPF)?

What is the bottom line?
========================

-   Using established Delphi and nominal group techniques supplemented by patient input, a preliminary core set of outcome measures in CTD-ILD and IPF have been identified.

Why read on?
============

-   To learn the core set of clinically meaningful and feasible measures in CTD-ILD and IPF that were identified and the gaps remaining.

Background {#s1}
==========

The diffuse idiopathic interstitial pneumonias describe a spectrum of parenchymal lung diseases sharing clinical, physiological, radiological and pathological similarities, including varying degrees of fibrosis, inflammation and vascular injury.[@R1] Idiopathic pulmonary fibrosis (IPF) is associated with usual interstitial pneumonia (UIP), poor survival and limited treatment options.[@R2] Interstitial lung disease (ILD), most typically presenting as non-specific interstitial pneumonitis, is a leading cause of death in systemic sclerosis (SSc)[@R3] and a prominent clinical feature of other connective tissue diseases (CTDs), including idiopathic inflammatory myopathy (IIM) and Sjögren syndrome. UIP is also found in rheumatoid arthritis (RA) and IIM.[@R4] [@R5]

Current evaluations of therapies focus on patient survival or markers of chronic disease progression, for example, change in forced vital capacity (FVC).[@R6] Measures of patient function, for example, 6 min walk test (6MWT), and health-related quality of life (HRQoL) have been variably applied with inconsistent results.[@R6] Therapeutic research has been hampered by lack of consensus on and validation of outcome measures that reliably assess the likelihood of treatment response. Furthermore, extra-pulmonary CTD manifestations may confound measures of ILD activity/severity. Patient-reported dyspnoea is demonstrated to predict time to death, yet a satisfactory dyspnoea instrument for ILD has not yet been identified.[@R7] [@R8] Clinically relevant, patient-reported outcome measures (PROMs) exist for obstructive lung disease and, in the absence of disease-specific measures, have been utilised in trials of ILD.

The Outcome Measures in Rheumatology (OMERACT) filter[@R9] (see online supplement) is a dynamic and iterative process/structure through which an instrument\'s performance can be evaluated under three criteria or points of examination: *truth* (face, content, construct and criterion validity), *discrimination* (reliability, sensitivity to change) and *feasibility* (cost, interpretability, accessibility, safety, time). The ideal instrument satisfies all three while instruments incompletely satisfying the filter may still be immediately useful but require additional study.

The Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) working group of the OMERACT international consensus initiative convened to define outcome measures for use in randomised controlled trials (RCTs) in CTD-ILD. Given the major clinical overlap, the same process was used in parallel for IPF. We report the results of a three-component process: medical expert Delphi exercise, patient perspective investigations and a combined medical expert and patient participant nominal group technique (NGT) meeting leading to identification of preliminary core sets of domains with corresponding instruments that are clinically meaningful and feasible in the context of a 1-year multi-centre RCT for each CTD-ILD and IPF. These sets of instruments are proposed as the minimum outcome measures to be used in future RCTs and registries.

Methods {#s2}
=======

Medical expert Delphi process {#s2a}
-----------------------------

### Delphi {#s2a1}

International experts (n=270) were identified by authorship in peer-reviewed journals, specialty society membership and peer recommendations, and invited to participate in the web-based Delphi process.[@R10] This began with an 'item-collection' stage called Tier 0, wherein participants nominated an unrestricted number of potential domains (qualities to measure) and instruments (specific tools for use as a measure) perceived as relevant for inclusion in a hypothetical 1-year RCT. This exercise produced a list of \>6700 items---reduced only for redundancy, organised into 23 domains and 616 instruments and supplemented by expert advisory teams of pathologists and radiologists. The results of Tier 0 provided the content for sequential web-based surveys: Tiers 1, 2 and 3 which progressively reduced the number of voting items as the items with the lowest ratings were dismissed. Survey items for each CTD-ILD and IPF were aligned in parallel and rated along a nine-point Likert scale from 1 ('not at all important') to 9 ('absolutely important'), with 'insufficiently familiar' a voting alternative. An extensive online repository of item-related journal articles was available to participants throughout the process.

### Analysis {#s2a2}

A cut-off of \<4 (median rating) was applied to ratings from the large number of voting items in Tier 1. Cluster analyses were applied to the ratings in Tiers 2 and 3 avoiding the use of an arbitrary cut-off, thus allowing items to aggregate independently providing an unbiased analysis of agreement among raters.[@R12] A nine-cluster analysis was initially applied and reduced to three clusters for all items during both tiers.

Patient perspective investigation {#s2b}
---------------------------------

Patient participation is recognised as integral to development of outcome measures by OMERACT, the US Food and Drug Administration and European Medicines Agency.[@R9] [@R13] To investigate the patient perspective in CTD-ILD, a set of qualitative studies were conducted: focus groups (60--90 min) of 8--12 consented participants with CTD-ILD were selected by convenience sampling and asked 1) how their life has changed since the diagnosis of their lung disease? and 2) how their lung disease has changed over time? Patient perspective data in 20 English-speaking patients with IPF were previously available.[@R14] Content was extracted from verbatim transcripts and inductive analysis was applied to minimise investigator bias.[@R15] Following each focus group, CTD-ILD participants (study patients with IPF were not available) rated on a seven-point Likert scale the importance of the domains identified in Tier 0 of the medical expert Delphi process.

NGT meeting {#s2c}
-----------

At the 2012 OMERACT 11 conference and the 2012 American Thoracic Society (ATS) International Conference, data from the Delphi and the patient perspective investigations were reviewed by medical and patient experts. Following this, a face-to-face meeting was held to apply NGT to the overall results.

At the NGT, evaluation of each domain was led by assigned teams of medical and patient participants who presented evidence-based reviews focusing on instrument validation in accordance with the OMERACT filter.[@R9] [@R12] Several weeks prior to team assembly, interactive educational sessions with the patient participants examined each domain and instrument. The teams served as a resource for evidence-based information during the discussion phases.

After each team presentation, all participants engaged in a 'round-robin' discussion allowing equal speaking time per participant[@R10] over two to three rounds examining acceptance or rejection of an item, potential clinical endpoint assignment, and determination for new instrument development within that domain. Each round of discussions was followed by group voting.

All participants were requested to register a vote for each item. With participants' full knowledge, responses from all physicians and patients with CTD-ILD were tabulated for CTD-ILD, with only those from pulmonologists and patients with IPF for IPF. All votes were recorded. (The radiologist voting was tabulated as a pulmonologist.) A priori, acceptance was agreed upon as ≥70% affirmative votes.[@R16] Voting addressed inclusion/exclusion of items based on the OMERACT filter and whether the patient perspective and evidence-based data warranted the need for new instrument development for that corresponding domain.

Results {#s3}
=======

Medical expert Delphi {#s3a}
---------------------

A total of 254 (137 pulmonologists, 113 rheumatologists and 4 cardiologists) engaged in the Delphi process. Seventy-four per cent reported their primary field of interest being ILD. Participation through all stages exceeded 97%. Six domains identified were: *Dyspnoea*, *HRQoL*, *Lung Physiology/Function*, *Lung Imaging and Survival*, and *Medications* for each CTD-ILD and IPF. Eighteen instruments were identified for each CTD-ILD and IPF ([tables 1](#THORAXJNL2013204202TB1){ref-type="table"}[](#THORAXJNL2013204202TB2){ref-type="table"}[](#THORAXJNL2013204202TB3){ref-type="table"}--[4](#THORAXJNL2013204202TB4){ref-type="table"}).

###### 

Reduction of domains and instruments in the Delphi process

  -------------------------------------------------------------------------------------------------------------
  Phase yielded   Analysis method      Domains\                 Instruments\                     Participant\
                                       CTD-ILD/IPF              CTD-ILD/IPF                      Dropout (%)
  --------------- -------------------- ------------------------ -------------------------------- --------------
  Tier 0          Intense review       133 nominations \>\>23   \>6700 nominations \>\>616/616   0

  Tier 1          \<4 median cut-off   21                       71/71                            2

  Tier 2          cluster analysis     13                       58/61                            \<1

  Tier 3          cluster analysis     5/5                      18/18                            0
  -------------------------------------------------------------------------------------------------------------

CTD-ILD, connective tissue disease associated interstitial lung disease; IPF, idiopathic pulmonary fibrosis.

###### 

Domain results of Tier 0

  Tier 0 results of 23 domains   
  ------------------------------ ------------------------------
  Survival                       Mental health
  Biomarkers                     Sleep
  Imaging                        Global assessment
  Lung physiology/function       HRQoL
  Lung parenchyma                Physical function
  Lung vascular                  Participation
  Cardiac function               Employment/work productivity
  Composite scores               Medication
  Gastroesophageal reflux        Extra-pulmonary CTD features
  Cough                          Comorbidities
  Dyspnoea                       Barriers to care
  Fatigue                        

CTD, connective tissue disease; HRQoL, health-related quality of life.

###### 

Results of the Delphi Tier 3 cluster analysis of domains with median/mean reported

  Five domains identified for each CTD-ILD and IPF               
  -------------------------------------------------- ----------- -----------
  Dyspnoea                                           (8.0/7.8)   (8.0/8.1)
  Health-related quality of life                     (8.0/7.7)   (8.0/7.8)
  Lung imaging                                       (9.0/8.3)   (9.0/8.3)
  Lung physiology/function                           (9.0/8.7)   (9.0/8.7)
  Survival                                           (8.0/8.2)   (9.0/8.4)
  Medications                                        (8.0/7.2)   (7.0/7.3)

CTD-ILD, connective tissue disease associated interstitial lung disease; IPF, idiopathic pulmonary fibrosis.

###### 

Results from Tier 3 of Delphi

  Domain                                                                         Instrument                                           Acceptance in   
  ------------------------------------------------------------------------------ ---------------------------------------------------- --------------- -----
  Dyspnoea                                                                       Borg Dyspnea Index                                   CTD-ILD         IPF
  MRC Breathlessness (Chronic Dyspnea) Scale or the Modified MRC Dyspnea Scale   CTD-ILD                                              IPF             
  Borg Dyspnea Index pre and post exercise                                       CTD-ILD                                              --              
  HRQoL                                                                          Medical Outcomes Trust Short Form 36 health survey   CTD-ILD         IPF
  St George\'s Dyspnoea Respiratory Questionnaire                                --                                                   IPF             
  Visual analogue scale of Patient Assessment of Disease Activity                CTD-ILD                                              IPF             
  Ability to carry out activities of daily living                                CTD-ILD                                              --              
  Health Assessment Questionnaire Disability Index                               CTD-ILD                                              --              
  Lung imaging                                                                   Extent of honeycombing on HRCT                       CTD-ILD         IPF
  Extent of reticulation on HRCT                                                 --                                                   IPF             
  Extent of ground glass opacities on HRCT                                       CTD-ILD                                              --              
  Overall extent of ILD on HRCT                                                  CTD-ILD                                              IPF             
  Lung physiology/function                                                       Supplemental oxygen requirement                      CTD-ILD         IPF
  FVC on spirometry                                                              CTD-ILD                                              IPF             
  Diffusion capacity of lung for carbon monoxide                                 CTD-ILD                                              IPF             
  6MWT with maximal desaturation on pulse oximetry                               CTD-ILD                                              IPF             
  6MWT for distance                                                              --                                                   IPF             
  Survival                                                                       Time to decline in FVC                               CTD-ILD         IPF
  Progression-free survival                                                      CTD-ILD                                              IPF             
  Time to death                                                                  --                                                   IPF             
  Medications                                                                    Increase or decrease in glucocorticoids              CTD-ILD         IPF
  Increase or decrease in concomitant immune suppressive agents                  CTD-ILD                                              IPF             

6MWT, 6 min walk test; CTD-ILD, connective tissue disease associated interstitial lung disease; FVC, forced vital capacity; HRCT, high-resolution CT; IPF, idiopathic pulmonary fibrosis; HRQoL, health-related quality of life; MRC, Medical Research Council.

Focus groups {#s3b}
------------

Focus groups were conducted with patients (n=45) in IIM-ILD (n=11), RA-ILD (n=13), SSc-ILD (n=17) and other CTD diagnoses (n=4) ([table 5](#THORAXJNL2013204202TB5){ref-type="table"}). Patient participants attributed importance to cough, dyspnoea, fatigue, participation (in family, social and leisure activities, work within and outside the home), physical function, self-care and sleep in the questionnaire and the focus groups. Changes in cough were perceived as reflecting potential worsening ILD. Dyspnoea largely carried descriptors different from current instruments. Patients with IPF identified cough, dyspnoea and HRQoL effects as central symptoms.[@R14]

###### 

Characteristics of patients with CTD-ILD participating in the focus groups

  -----------------------------------------------------------------------------------------------------------
  Group   CTD type   Location                      Participants    Gender     Age (years)\   Race
                                                                              Mean (SD)      
  ------- ---------- ----------------------------- --------------- ---------- -------------- ----------------
  1       Various    Winnipeg, Manitoba, Canada    9\              8 F, 1 M   53.6 (16.2)    8 C, 1 O
                                                   1 IIM, 2 RA,\                             
                                                   4 SSc, 2 SLE                              

  2       RA         Toronto, Canada               7               7 F, 0 M   64.3 (9.0)     4 C, 2 A, 1 AC

  3       SSc        Baltimore, Maryland, USA      6               3 F, 3 M   58.2 (9.1)     6 C

  4       IIM        Baltimore, Maryland, USA      7               4 F, 3 M   52.4 (10.5)    5 C; 2 AA

  5       Various    New Orleans, Louisiana, USA   9\              6 F; 3 M   53.8 (15.5)    4 C; 4 AA; 1 H
                                                   3 IIM, 4 RA,\                             
                                                   1 SjS, 1 SLE                              

  6       SSc        New Orleans, Louisiana, USA   7               5 F; 2 M   54.6 (5.7)     4 AA; 3 C
  -----------------------------------------------------------------------------------------------------------

A, Asian; AA, African American; AC, African Caribbean; C, Caucasian; CTD-ILD, connective tissue disease associated interstitial lung disease; F, female; H, Hispanic; IIM, idiopathic inflammatory myopathy; M, male; O, other; RA, rheumatoid arthritis; SjS, Sjögren\'s syndrome; SLE, systemic lupus erythematosus.

OMERACT 11/ATS 2012/Domain Team meetings {#s3c}
----------------------------------------

Discussions and voting at the OMERACT 11/ATS 2012/Domain Team meetings resulted in the following changes based on the patient perspective data or strong evidence in recent literature (detailed in online supplement): *Cough* was reintroduced, discussed and voted upon at the NGT.To satisfy the reintroduction of *Cough*, Leicester Cough Questionnaire (LCQ) was introduced as an interim instrument to assess *Cough*.The Mahler Dyspnea Index (MDI) and University of California San Diego Shortness of Breath Questionnaire (UCSD-SBQ) were reintroduced under *Dyspnoea* for use in CTD-ILD and IPF, respectively, based on substantive findings in an updated literature review.For feasibility, *HRQoL* would capture 'fatigue', 'participation', 'physical function', 'self-care' and 'sleep' until disease-specific investigations into these components were conducted.NGT voting would include whether development of new instruments for *Dyspnoea*, *Cough* and *HRQoL* are needed.Owing to variability of therapies, concern regarding *Medications* as a core domain was expressed. However, being identified as important in the Delphi, a statement of clarification would be constructed at the NGT.'All-Cause Mortality' was introduced as an assessment of 'Survival'.

NGT results {#s3d}
-----------

The final NGT panel included 10 pulmonary experts, 12 rheumatology experts and 1 radiology expert, with 5 patient partners ([tables 6](#THORAXJNL2013204202TB6){ref-type="table"}[](#THORAXJNL2013204202TB7){ref-type="table"}--[8](#THORAXJNL2013204202TB8){ref-type="table"}, and see online supplement).

###### 

Results of nominal group proceedings with percentage for acceptance (see online supplement for expanded voting tables)

  -------------------------------------------------------------------------------------------
  Instrument                       CTD-ILD\                           IPF\
                                   PULM+RHEUM+patients with CTD-ILD   PULM+patient with IPF
  -------------------------------- ---------------------------------- -----------------------
  Dyspnoea                                                            

   MRC Chronic Dyspnea Scale       7/9+9/12+2/3=75%                   10/11+1/1=92%

   Dyspnea 12                      8/10+11/12+3/3=88%                 6/9+1/1=70%

   UCSD-SBQ                        N/A                                7/9+1/1=80%

  Cough                                                               

   Leicester cough questionnaire   7/10+10/12+2/2=79%                 8/10+1/1=82%

  HRQoL                                                               

   Short Form 36                   10/10+11/11+3/3=100%               8/10+1/1=82%

   SGRQ                            9/10+9/11+2/2=87%                  8/10+1/1=82%

   VAS-PtGA                        10/10+11/12+2/2=96%                N/A

  Lung imaging                                                        

   Overall extent of ILD on HRCT   11/11+9/11+3/3=92%                 10/10+1/1=100%

  Lung physiology                                                     

   Forced vital capacity           10/10+11/11+3/3=100%               10/10+1/1=100%

   Diffusion capacity of lung      10/10+8/10+3/3=91%                 10/10+1/1=100%

  Survival                                                            

   All-cause mortality             Unanimous agreement                Unanimous agreement
  -------------------------------------------------------------------------------------------

CTD-ILD, connective tissue disease associated interstitial lung disease; HRCT, high-resolution CT; HRQoL, health-related quality of life; IPF, idiopathic pulmonary fibrosis; MRC, Medical Research Council; PtGA, Patient Global Assessment; PULM, pulmonary specialist; RHEUM, rheumatology specialist; SGRQ, St George\'s Respiratory Questionnaire; UCSD-SBQ, University of California San Diego Shortness of Breath Questionnaire; VAS, visual analogue scale.

###### 

Relation of CTD-ILD preliminary core set instruments to aspects of OMERACT filter in CTD-ILD

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  CTD-ILD                    Dyspnoea         Cough   HRQoL                  Lung\               Lung\                     Survival     
                                                                             physiology          imaging                                
  -------------------------- ---------- ----- ------- ------- ------- ------ ------------ ------ ------------------------- ------------ ------------------
  Instruments                D-12       MRC   LCQ     SGRQ    SF-36   PtGA   FVC          DLCO   HRCT---overall\           All-cause\   Time to decline\
                                                                                                 extent of disease         mortality    in FVC

  Truth                                                                                                                                 

   Face validity             Y          Y     Y       Y       Y       Y      Y            Y      Y                         Y            Y

   Content validity          Y          Y     Y       Y       Y       Y      Y            Y      Y                         Y            Y

   Construct validity        Y          Y     NT      Y       Y       NT     Y            ±      Y                         Y            NT

   Criterion validity        NT         NT    NT      NT      NT      NT     No           No     Y                         Y            NT

  Discrimination                                                                                                                        

   Discriminatory            Y          Y     NT      Y       Y       NT     ±            ±      Yes, except± for GGO      No           Y

   Reliable                  Y          Y     NT      NT      Y       NT     Y            N      Yes, except± for GGO      Y            NT

   Reproducible              NT         NT    NT      NT      NT      NT     Y            ±      Y                         N/A          NT

   Sensitive to change       Y          Y     NT      NT      Y       NT     Y            ±      Yes but relatively slow   N/A          Y

  Feasibility                                                                                                                           

   Cost effective            Y          Y     Y       Y       Y       Y      Y            Y      Y                         No\*         Y

   Interpretability          Y          Y     Y       Y       Y       Y      Y            Y      Y                         Y            Y

   Readily available         Y          Y     Y       Y       Y       Y      Y            Y      Y                         Y            Y

   Safe for patients         Y          Y     Y       Y       Y       Y      Y            Y      ±                         Y            Y

  Patient-derived content†   Y          No    No      No      No      N/A    N/A          N/A    N/A                       N/A          N/A
  --------------------------------------------------------------------------------------------------------------------------------------------------------

PtGA is adopted under HRQoL, though it is an independent instrument.

\*Not cost effective as a primary efficacy endpoint but highly cost effective as a secondary endpoint to detect treatment toxicity---see text for discussion on 'survival'

†US Food and Drug Administration advocates patient-reported instruments be developed by qualitative data supplied by patients.[@R18] [@R19]

±, ambiguous; CTD-ILD, connective tissue disease associated interstitial lung disease; D-12, Dyspnea-12; DLCO, diffusion capacity of lung for carbon monoxide; FVC, forced vital capacity; GGO, ground glass opacity; HRCT, high-resolution CT; LCQ, Leicester Cough Questionnaire; MRC, Medical Research Council Dyspnea Scale; N/A, not applicable; NT, not yet tested; OMERACT, Outcome Measures in Rheumatology; PtGA, Patient Global Disease Activity; SGRQ, St George\'s Respiratory Questionnaire; SF-36, Short Form 36; Y, yes.

###### 

Relation of IPF preliminary core set instruments to aspects of OMERACT filter in IPF

  -------------------------------------------------------------------------------------------------------------------------------------
  IPF                         Dyspnoea   Cough   HRQoL   Lung\        Lung\     Survival                                         
                                                         physiology   imaging                                                    
  --------------------------- ---------- ------- ------- ------------ --------- ---------- ----- ----- ------------------------- ------
  Truth                                                                                                                          

   Face validity              Y          Y       Y       Y            Y         Y          Y     Y     Y                         Y

   Content validity           Y          Y       Y       Y            Y         Y          Y     Y     Y                         Y

   Construct validity         Y          Y       Y       NT           Y         Y          Y     Y     Y                         Y

   Criterion validity         NT         NT      NT      NT           NT        NT         No    No    Y                         Y

  Discrimination                                                                                                                 

   Discriminatory             NT         NT      Y       NT           NT        NT         ±     ±     Y                         No

   Reliable                   NT         NT      NT      NT           Y         Y          Y     N     Y                         Y

   Reproducible               NT         NT      NT      NT           Y         NT         Y     ±     Y                         N/A

   Sensitive to change        NT         NT      Y       NT           Y         Y          Y     Y     Yes but relatively slow   N/A

  Feasibility                                                                                                                    

   Cost effective             Y          Y       Y       Y            Y         Y          Y     Y     Y                         No\*

   Interpretability           Y          Y       Y       Y            Y         Y          Y     Y     Y                         Y

   Readily available          Y          Y       Y       Y            Y         Y          Y     Y     Y                         Y

   Safe for patients          Y          Y       Y       Y            Y         Y          Y     Y     ±                         Y

   Patient-derived content†   Y          No      No      No           No        No         N/A   N/A   N/A                       N/A
  -------------------------------------------------------------------------------------------------------------------------------------

\*Not cost effective as a primary efficacy endpoint but highly cost effective as a secondary endpoint to detect treatment toxicity---see text for discussion on 'survival'.

†US Food and Drug Administration advocates patient-reported instruments be developed by qualitative data supplied by patients.[@R18] [@R19]

±, ambiguous; D-12, Dyspnea-12; DLCO, diffusion capacity of lung for carbon monoxide; FVC, forced vital capacity; HRCT, high-resolution CT; IPF, idiopathic pulmonary fibrosis; LCQ, Leicester Cough Questionnaire; MRC, Medical Research Council Dyspnea Scale; N/A, not applicable; NT, not yet tested; OMERACT, Outcome Measures in Rheumatology; SGRQ, St George\'s Respiratory Questionnaire; SF-36, Short Form 36; UCSD, University of San Diego Shortness of Breath Questionnaire; Y, yes.

[Table 6](#THORAXJNL2013204202TB6){ref-type="table"} displays the voting results on instruments for CTD-ILD and IPF with striking concurrence in all domains except for *HRQoL*, for which Patient Global Assessment (PtGA) was not accepted by the pulmonary experts for IPF.

[Tables 7](#THORAXJNL2013204202TB7){ref-type="table"} and [8](#THORAXJNL2013204202TB8){ref-type="table"} present the content of the NGT discussions in the context of the OMERACT filter with items of special interest highlighted below.

It was agreed that 'Medications' (ie, the incremental increase/decrease of glucocorticoid and/or immunosuppressive therapy) should be viewed as protocol specific rather than a core domain. Depending on study design, 'Medications' may be either a dichotomous interpretation of treatment efficacy/failure or a reflection of changes in disease activity.

The lack of validated biomarkers was fully discussed. No items for bio-specimen evaluation emerged from the Delphi exercise but the importance of future biomarker research was planned for during the meeting. Consensus is required to define the minimal standards for investigation-related bio-banking and systematic access to samples by investigators.[@R17]

Discussion {#s4}
==========

These comprehensive international investigations are the first to identify core sets of domains in each CTD-ILD and IPF along with a *provisional* consensus on a minimum cadre of feasible and clinically meaningful outcome measures/instruments. The proposed measures are intended to be a common denominator across future RCTs, longitudinal observational studies and natural history registries until work can be done that substantiates a truly durable framework. The rigorous consensus methodologies of OMERACT outline the overall status of the field. Importantly, this is the first study in ILD to incorporate patient participants in panel meetings or guidelines. From the synergy of these investigations, domains which require development of new instruments were also identified, thus providing guidance for imminent research.

Based on the current data, FVC (100% acceptance) was the measure that the group favoured most for each CTD-ILD and IPF. Again, we emphasise that the overarching construct of this exercise was limited to that of a hypothetical RCT of 1-year duration. FVC has been shown to be a consistently reliable serial variable in IPF. Declines in FVC correlate with increased risk of subsequent mortality,[@R4] [@R7] [@R8] [@R18] although no data exist demonstrating that improvement in FVC correlates with improved survival. Thus, utilising FVC as an endpoint requires consideration of the clinically meaningful magnitude of change independent of potential impact on mortality. This is particularly relevant in studies of short duration.

While changes in FVC have been shown to be reproducible in SSc-ILD, there are insufficient RCT-derived data to evaluate this in other forms of CTD-ILDs.[@R3] [@R20] There are confounding issues of vasculopathy, pulmonary hypertension, cardiac involvement, chest wall impairment and systemic disease activity that are often coexistent in CTD-ILDs. Nonetheless, FVC may most reliably and sensitively reflect the contribution of parenchymal disease above other endpoints.

Though a relative change from baseline predicted is preferred to absolute change from normal values, these changes are recognised as non-parametric in FVC. Thus a discrete clinically relevant threshold of minimal change was not able to be agreed upon in either IPF or CTD-ILD. Further, efforts to validate serial variables are challenged by variations in the rate of disease progression, with interval changes of FVC[@R20] [@R22] more likely to represent a true change in rapidly progressive disease than in less progressive disease that crosses the same threshold. Extrapolation between two value points will provide less reliable information than continuous variables; therefore, identification of a minimal clinically important difference (MCID) would be misleading without accommodating for these non-parametric changes. Panel discussions surrounding Diffusion Capacity of Lung for Carbon Monoxide (DLCO) reflected the multiple confounders for this instrument, with ranking of FVC as being the favoured marker above DLCO. A threshold of clinically meaningful change was not determined for DLCO.

Neither the 6MWT nor measures of oxygen desaturation survived the NGT process; although deemed feasible they were considered weak in discrimination in addition to construct and criterion validity. The need for supplemental oxygen was not accepted; changes in oxygenation, as judged partly by oxygen desaturation, are difficult to interpret since they do not correlate well with the sensation of dyspnoea or changes in disease progression in mild to moderate disease.[@R19] [@R23]

The importance of patient-reported dyspnoea for assessing prognosis and disease progression are well recognised.[@R1] [@R7] [@R8] We identified the Dyspnea 12[@R24] and the Medical Research Council Dyspnea Scale[@R18] [@R19] as the best currently available instruments in CTD-ILD and in IPF, yet data are essentially lacking in CTD-ILD. Though the MDI has some demonstrated validity in SSc-ILD[@R20], NGT panelists allocated this interviewer-administered instrument to the research agenda for CTD-ILD, voicing concerns of poor feasibility and uncertain reliability. The UCSD-SBQ was accepted for use in studying IPF.[@R21] It was agreed that development of new *Dyspnoea* instruments is warranted to specifically reflect the restrictive lung processes of CTD-ILD and IPF.

The Short Form 36 (SF-36) was recognised as a generic *HRQoL* instrument as anxiety, fatigue, participation, physical function, self-care and sleep are important to patients.[@R25] The St George\'s Respiratory Questionnaire, although endorsed, lacked specificity in CTD-ILD and IPF.[@R26] [@R27] It was agreed that a new disease-specific instrument should be developed.

PtGA, previously validated across rheumatic and non-rheumatic diseases, correlates with dyspnoea in CTD-ILD[@R28] [@R29] and was accepted as a measure in CTD-ILD with improvements greater than 10 mm agreed upon as an MCID. PtGA not being validated in IPF was allocated to the research agenda in IPF. PtGA may also serve as an 'anchor' to determine MCIDs for recently developed PROMs, such as the King\'s Brief ILD Health Assessment Questionnaire (K-BILD).[@R30]

The extent of ground-glass opacities, honeycombing and/or reticulations on high-resolution CT (HRCT) scan each merited careful consideration as outcome measures. However, taken separately each was felt to incompletely capture disease progression in either CTD-ILD or IPF. The overall extent of ILD on HRCT was accepted to provisionally describe the most appropriate and feasible composite of radiological abnormalities to monitor for disease progression.[@R31] [@R32] No specific assessment tool at this time was able to be confidently identified as it is not yet clear whether subjective or automated objective assessment is the more accurate approach. Though serial HRCT raises concern for patient safety, validation studies of less radio-intense methods of HRCT serial assessment[@R33] are underway.

Progression-free survival in IPF was agreed to have merit,[@R34] however the group was undecided as to the practicality of this endpoint in the context of a trial limited to 1 year\'s duration. Mortality was minimal or absent in two recent RCTs of SSc-ILD.[@R35] [@R36] There are cogent arguments for and against survival as the primary outcome in studies of IPF.[@R34] [@R37] Regardless of this unresolved debate, mortality was recognised as an essential endpoint in all treatment trials as it provides a harm signal,[@R34] [@R37] with all-cause mortality identified as a valid measure of survival in CTD-ILD and IPF. The utility of other measures of progression-free survival in RCTs requires further investigation of candidate instruments before recommending their use in RCTs.

While the domain of *Cough* did not survive the Delphi process, it was important to patient participants. Additionally, there is a correlation between cough and IPF progression[@R38] and with ILD severity in SSc.[@R39] In SSc-ILD, cough adversely impacted HRQoL and improved with treatment.[@R39] The LCQ was selected as an interim measure as it was deemed more able to capture frequency, quality and intensity, and impact on HRQoL. It was also most feasible to administer.[@R40] [@R41]

Primary and secondary endpoint status of the proposed measures were considered, intensely discussed and even voted upon during the NGT. However, at this preliminary stage and given the lack of full validation of the core measures, the consensus was to pursue further data. A more careful approach to endpoint status declarations entails ad hoc and prospective performance analyses of these measures.

Though we recommend these proposed measures for all future research ventures, continued use of measures outside this core set, for clinical practice and research purposes, is fully expected with further research into their performance anticipated and necessary. Rather, this endeavour defines the currently available, best validated and feasible instruments while providing a much needed prioritised research agenda focus to the research community.

This project applied rigorous multi-investigational processes that captured the perspectives of the international ILD expert community and the life experience of patients with ILD to identify a set of domains and measures. Participation remained robust through all tiers of the consensus process.

The importance of patient participation is supported by the incorporation of *HRQoL*, *Participation* and *Fatigue* in the RA core set for RCTs. From a practical perspective, qualitative data collection involved only English-speaking patients from North America, and results may be affected by cultural, environmental and resource-related effects requiring further investigations to follow up our reported findings. Nevertheless, the engagement of patients as partners in the iterative process was important in identifying and re-capturing areas of potentially meaningful measures of disease activity.

Conclusions {#s5}
===========

It is critical that valid and clinically useful instruments be developed and validated to assess the likelihood of treatment response in these disorders. Identification of consensus preliminary domains and instruments to measure them was attained and is a major advance anticipated to facilitate multicentre RCTs in the field. However, none of the provisional endpoints were ultimately felt to be either ideal or fully validated. Feasible endpoints like FVC are not perfect; more rigorous endpoints like mortality, particularly in the setting of CTD-ILD, lack feasibility. Thus, selecting the best non-ideal endpoints from a larger group of non-ideal endpoints still leaves us with much work which includes further validation of existing and development of new instruments.
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